Positive Data But Uphill Struggle For Takeda’s Trelagliptin?
This article was originally published in PharmAsia News
Executive Summary
Takeda has released the first detailed late-stage clinical results for trelagliptin, showing positive data for the once-weekly DPP-4 inhibitor, which is currently awaiting Japanese approval for type 2 diabetes. But a number of factors may play on the drug’s commercial prospects.